Lessons from precision medicine in rheumatology. (April 2020)

• Record Type: Journal Article
• Authors: Wampler Muskardin, Theresa L; Paredes, Jacqueline L; Appenzeller, Simone; Niewold, Timothy B
• Other Names: Chitnis Tanuja guest-editor.; Prat Alexandre guest-editor.
• Is Part Of: Multiple sclerosis. Volume 26:Number 5(2020)
• Page Start: 533
• Page End: 539
• Publication Date: 2020-04
• Subjects: Beta-interferon -- immunology -- biomarkers -- genetics -- neuromyelitis optica; Central nervous system -- Diseases -- Periodicals; Myelin sheath -- Diseases -- Periodicals; Inflammation -- Periodicals; Multiple sclerosis -- Periodicals; Central Nervous System Diseases -- Periodicals; Demyelinating Diseases -- Periodicals; Inflammation -- Periodicals; Multiple Sclerosis -- Periodicals; Système nerveux central -- Maladies -- Périodiques; Gaine de myéline -- Maladies -- Périodiques; Inflammation (Pathologie) -- Périodiques; Sclérose en plaques -- Périodiques; Electronic journals; 616.834005
• DOI: 10.1177/1352458519884249
• Languages: English
• ISSNs: 1352-4585

Abstract

Systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) are two common autoimmune rheumatic diseases that vary in severity, clinical presentation, and disease course between individuals. Molecular and genetic studies of both diseases have identified candidate genes and molecular pathways that are linked to various disease outcomes and treatment responses. Currently, patients can be grouped into molecular subsets in each disease, and these molecular categories should enable precision medicine approaches to be applied in rheumatic diseases. In this article, we will review key lessons learned about disease heterogeneity and molecular characterization in rheumatology, which we hope will lead to personalized therapeutic strategies.